Effectiveness of Dp2 nasal therapy for Dp2- induced airway inflammation in mice: using oral Ganoderma lucidum as an immunomodulator.

Nasal immunotherapy with allergen has been reported to be effective for airway allergic disease. A group of 50 male Balb/c mice were immunized intraperitoneally with recombinant Dermatophagoides pteronyssinus group 2 (rDp2), then oral feeding with Ganoderma lucidum (known as "Ling Zhi," LZ OT) and intranasal therapy with native Dp2 (Dp2 NT) were given, the mice then received intratracheal challenge with rDp2 at 28 days and 35 days after immunization. Airway hypersensitivity to methacholine was measured 30 min (early phase) and 24 h (late phase) after the second challenge.